---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-135733"
form_type: "8-K"
ticker: null
cik: "0001744659"
company_name: "Akero Therapeutics, Inc."
filed_at: "2024-05-10T23:59:59+00:00"
generated_at: "2026-06-02T04:00:12.338696+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Akero Q1 2024 cash $903.7M; Phase 2b HARMONY week 96 fibrosis improvement 75% for 50mg EFX

## Summary
- Cash, equivalents and short-term marketable securities $903.7M as of March 31, 2024; March equity offering raised ~$366.9M gross.
- Phase 2b HARMONY Week 96: 75% (50mg) and 46% (28mg) achieved ≥1-stage fibrosis improvement without MASH worsening vs 24% placebo (p<0.001 and p=0.07).
- 36% (50mg) and 31% (28mg) showed 2-stage fibrosis improvement vs 3% placebo (p<0.01).
- Total operating expenses $60.0M vs $28.8M YoY on increased R&D for Phase 3 studies.
- Phase 3 SYNCHRONY Histology and Real-World enrolling; Outcomes trial on track to start Q2 2024.

## SEC filing metadata
- accession: 0001193125-24-135733
- form_type: 8-K
- cik: 0001744659
- company_name: Akero Therapeutics, Inc.
- filed_at: 2024-05-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1744659/000119312524135733/0001193125-24-135733-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1744659/000119312524135733/d836734d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-135733
- JSON: https://secwatch.observer/filing/0001193125-24-135733.json
- Plain text: https://secwatch.observer/filing/0001193125-24-135733.txt

## Key facts
- Earnings Releases
  Akero Therapeutics, Inc. reported financial results for the quarter ended March 31, 2024.
  - Period: the quarter ended March 31, 2024
  - Result: reported results
  source text: On May 10, 2024, Akero Therapeutics, Inc. announced its financial results for the quarter ended March 31, 2024.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1744659/000119312524135733/0001193125-24-135733-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.